This is a multicenter, randomized, open label study designed to evaluate the efficacy and
safety of prolonged treatment with bortezomib twice monthly and dexamethasone after a salvage
treatment containing bortezomib for relapsed or refractory multiple myeloma patients.
Phase:
Phase 2
Details
Lead Sponsor:
European Myeloma Network Stichting Hemato-Oncologie voor Volwassenen Nederland